Evidence map›Paper›PMID 34949766›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022

Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.

Talia L Fuchs, Fiona Maclean, John Turchini, A Cristina Vargas, Selina Bhattarai, Abbas Agaimy, Arndt Hartmann, Chia-Sui Kao, Carla Ellis, Michael Bonert and 34 more

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Succinate dehydrogenase deficient renal cell carcinoma frequently expresses GATA3 and L1CAM.Virchows Archiv : an international journal of pathology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. [Succinate Dehydrogenase-Deficient Renal Cell Carcinoma: Clinicopathological Analysis of 11 Cases].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors at 20 institutions in 13 countries.

Talia L Fuchs *Sydney Medical School, The University of Sydney, Sydney, Australia.ORCID 0000-0002-9166-6822
Fiona Maclean *Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
John TurchiniSydney Medical School, The University of Sydney, Sydney, Australia.
A Cristina VargasSydney Medical School, The University of Sydney, Sydney, Australia.ORCID 0000-0003-3798-5088
Selina BhattaraiLeeds Teaching Hospital, Leeds, UK.
Abbas AgaimyInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-0445-8161
Arndt HartmannInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Chia-Sui KaoStanford University Medical Center, Stanford, CA, USA.
Carla EllisNorthwestern University, Chicago, IL, USA.
Michael BonertMcMaster University, Hamilton, Ontario, Canada.
Xavier LeroyInstitut de Pathologie, Centre de Biologie-Pathologie, CHRU, Lille, France.
Lakshmi P KunjuUniversity of Michigan, Ann Arbor, MI, USA.
Lauren SchwartzUniversity of Pennsylvania, Philadelphia, PA, USA.
Admire MatsikaMater Health, Brisbane, QLD, Australia.
Sean R WilliamsonRobert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Cleveland, Ohio, OH, USA.ORCID 0000-0002-3898-1460
Priya RaoThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mukul DivatiaHouston Methodist Hospital, Houston, TX, USA.
Rosa GuarchComplejo Hospitalario de Navarra, Navarra, Spain.
Ferran AlgabaFundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain.
Marcelo L BalancinOncocentro Foundation, Sao Paulo, Brazil.
Ming ZhouTufts Medical Center, Boston, MA, USA.
Hemamali SamaratungaUniversity of Queensland, Brisbane, QLD, Australia.
Isabela Werneck da CunhaInstitute of Pathology, Rede D'OR-São Luiz and D'Or Institute for Research and Education (IDOR), São Paulo, Brazil.ORCID 0000-0002-2029-5139
Fadi BrimoMcGill University, Montreal, Canada.
Andrew RyanTissuPath Pathology, Melbourne, VIC, Australia.
David CloustonTissuPath Pathology, Melbourne, VIC, Australia.
Manju AronUniversity of Southern California, Los Angeles, CA, USA.
Marie O'DonnellNHS Lothian, Edinburgh, Scotland, UK.
Emily ChanUniversity of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7290-4004
Michelle S HirschBrigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8767-8564
Holger MochDepartment of Pathology and Molecular Pathology, University Hospital Zurich and University Zurich, Zurich, Switzerland.ORCID 0000-0002-7986-2839
Chun-Yin PangSt. Teresa's Hospital, Kowloon, Hong Kong, SAR, China.
Cheuk WahQueen Elizabeth Hospital, Kowloon, Hong Kong, SAR, China.
Weihua YinPeking University Shenzhen Hospital, Shenzhen, China.
Joanna Perry-KeeneAquesta Pathology, Toowong, QLD, Australia.
Asli YilmazDepartment of Pathology and Laboratory Medicine, University of Calgary and Alberta Precision Labs, Calgary, AB, Canada.
Angela ChouSydney Medical School, The University of Sydney, Sydney, Australia.
Adele ClarksonCancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
Gerhard van der WesthuizenPathCare, Mediclinic Bloemfontein Hospital, Bloemfontein, South Africa.
Ella MorrisonNHLS, Bloemfontein Area, Bloemfontein, South Africa.
Jonathan ZwiLab Plus, Auckland DHB, Auckland, New Zealand.
Ondrej HesMedical Faculty and University Hospital Plzen, Charles University, Prague, Plzen, Czech Republic.
Kiril TrpkovDepartment of Pathology and Laboratory Medicine, University of Calgary and Alberta Precision Labs, Calgary, AB, Canada.ORCID 0000-0003-3142-8846
Anthony J GillSydney Medical School, The University of Sydney, Sydney, Australia. a.gill@sydney.edu.au.ORCID 0000-0002-9447-1967
The University of Sydney · AUFriedrich-Alexander-Universität Erlangen-Nürnberg · DETissuPath · AUUniversity of Calgary · CAAuckland District Health Board · NZBrigham and Women's Hospital · USCharles University · CZCleveland Clinic · USClinvet · ZAComplejo Hospitalario de Navarra · ESD’Or Institute for Research and Education · BRDouglass Hanly Moir Pathology · AUInstitut de Biologie de Lille · FRKowloon Hospital · CNLeeds Teaching Hospitals NHS Trust · GBMater Health Services · AUMcGill University · CAMcMaster University · CAMethodist Hospital · USNHS Lothian · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most succinate dehydrogenase (SDH)-deficient renal cell carcinomas (RCCs) demonstrate stereotypical morphology characterized by bland eosinophilic cells with frequent intracytoplasmic inclusions. However, variant morphologic features have been increasingly recognized. We therefore sought to investigate the incidence and characteristics of SDH-deficient RCC with variant morphologies. We studied a multi-institutional cohort of 62 new SDH-deficient RCCs from 59 patients. The median age at presentation was 39 years (range 19-80), with a slight male predominance (M:F = 1.6:1). A relevant family history was reported in 9 patients (15%). Multifocal or bilateral tumors were identified radiologically in 5 patients (8%). Typical morphology was present at least focally in 59 tumors (95%). Variant morphologies were seen in 13 (21%) and included high-grade nuclear features and various combinations of papillary, solid, and tubular architecture. Necrosis was present in 13 tumors, 7 of which showed variant morphology. All 62 tumors demonstrated loss of SDHB expression by immunohistochemistry. None showed loss of SDHA expression. Germline SDH mutations were reported in all 18 patients for whom the results of testing were known. Among patients for whom follow-up data was available, metastatic disease was reported in 9 cases, 8 of whom had necrosis and/or variant morphology in their primary tumor. Three patients died of disease. In conclusion, variant morphologies and high-grade nuclear features occur in a subset of SDH-deficient RCCs and are associated with more aggressive behavior. We therefore recommend grading all SDH-deficient RCCs and emphasize the need for a low threshold for performing SDHB immunohistochemistry in any difficult to classify renal tumor, particularly if occurring at a younger age.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAdultAgedAged, 80 and overFemaleHumansHyperplasiaImmunohistochemistryMaleMiddle AgedNecrosisSuccinate DehydrogenaseYoung AdultSuccinate Dehydrogenase

Identifiers

PMID34949766
OpenAlexW4200082979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.